Logo image of ACAD

ACADIA PHARMACEUTICALS INC (ACAD) Stock Overview

NASDAQ:ACAD - US0042251084 - Common Stock

25.57 USD
+0.25 (+0.99%)
Last: 8/26/2025, 1:41:09 PM

ACAD Key Statistics, Chart & Performance

Key Statistics
52 Week High25.95
52 Week Low13.4
Market Cap4.31B
Shares168.71M
Float167.74M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.45
PE56.82
Fwd PE29.6
Earnings (Next)11-04 2025-11-04/amc
IPO05-27 2004-05-27
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ACAD short term performance overview.The bars show the price performance of ACAD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15 20 25

ACAD long term performance overview.The bars show the price performance of ACAD in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40

The current stock price of ACAD is 25.57 USD. In the past month the price increased by 11.94%. In the past year, price increased by 52.71%.

ACADIA PHARMACEUTICALS INC / ACAD Daily stock chart

ACAD Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.61 366.83B
AMGN AMGEN INC 13.23 155.39B
GILD GILEAD SCIENCES INC 14.73 141.43B
VRTX VERTEX PHARMACEUTICALS INC 22.79 98.97B
REGN REGENERON PHARMACEUTICALS 12.82 62.01B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.61B
ARGX ARGENX SE - ADR 75.88 43.05B
ONC BEONE MEDICINES LTD-ADR 6.21 36.54B
INSM INSMED INC N/A 27.77B
BNTX BIONTECH SE-ADR N/A 25.03B
NTRA NATERA INC N/A 22.54B
BIIB BIOGEN INC 8.53 20.01B

About ACAD

Company Profile

ACAD logo image ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. The company is headquartered in San Diego, California and currently employs 653 full-time employees. The company went IPO on 2004-05-27. The company develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. The company has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

Company Info

ACADIA PHARMACEUTICALS INC

12830 El Camino Real, Suite 400

San Diego CALIFORNIA 92130 US

CEO: Stephen R. Davis

Employees: 654

ACAD Company Website

ACAD Investor Relations

Phone: 18585582871

ACADIA PHARMACEUTICALS INC / ACAD FAQ

What is the stock price of ACADIA PHARMACEUTICALS INC today?

The current stock price of ACAD is 25.57 USD. The price increased by 0.99% in the last trading session.


What is the ticker symbol for ACADIA PHARMACEUTICALS INC stock?

The exchange symbol of ACADIA PHARMACEUTICALS INC is ACAD and it is listed on the Nasdaq exchange.


On which exchange is ACAD stock listed?

ACAD stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ACADIA PHARMACEUTICALS INC stock?

26 analysts have analysed ACAD and the average price target is 30.32 USD. This implies a price increase of 18.56% is expected in the next year compared to the current price of 25.57. Check the ACADIA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ACADIA PHARMACEUTICALS INC worth?

ACADIA PHARMACEUTICALS INC (ACAD) has a market capitalization of 4.31B USD. This makes ACAD a Mid Cap stock.


How many employees does ACADIA PHARMACEUTICALS INC have?

ACADIA PHARMACEUTICALS INC (ACAD) currently has 654 employees.


What are the support and resistance levels for ACADIA PHARMACEUTICALS INC (ACAD) stock?

ACADIA PHARMACEUTICALS INC (ACAD) has a support level at 25.31 and a resistance level at 25.74. Check the full technical report for a detailed analysis of ACAD support and resistance levels.


Is ACADIA PHARMACEUTICALS INC (ACAD) expected to grow?

The Revenue of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 9.96% in the next year. Check the estimates tab for more information on the ACAD EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ACADIA PHARMACEUTICALS INC (ACAD) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ACADIA PHARMACEUTICALS INC (ACAD) stock pay dividends?

ACAD does not pay a dividend.


When does ACADIA PHARMACEUTICALS INC (ACAD) report earnings?

ACADIA PHARMACEUTICALS INC (ACAD) will report earnings on 2025-11-04, after the market close.


What is the Price/Earnings (PE) ratio of ACADIA PHARMACEUTICALS INC (ACAD)?

The PE ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 56.82. This is based on the reported non-GAAP earnings per share of 0.45 and the current share price of 25.57 USD. Check the full fundamental report for a full analysis of the valuation metrics for ACAD.


What is the Short Interest ratio of ACADIA PHARMACEUTICALS INC (ACAD) stock?

The outstanding short interest for ACADIA PHARMACEUTICALS INC (ACAD) is 6.65% of its float. Check the ownership tab for more information on the ACAD short interest.


ACAD Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ACAD. When comparing the yearly performance of all stocks, ACAD is one of the better performing stocks in the market, outperforming 88.64% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ACAD Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ACAD. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ACAD Financial Highlights

Over the last trailing twelve months ACAD reported a non-GAAP Earnings per Share(EPS) of 0.45. The EPS increased by 150% compared to the year before.


Industry RankSector Rank
PM (TTM) 21.8%
ROA 18.13%
ROE 27.01%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-20%
Sales Q2Q%9.34%
EPS 1Y (TTM)150%
Revenue 1Y (TTM)14.41%

ACAD Forecast & Estimates

26 analysts have analysed ACAD and the average price target is 30.32 USD. This implies a price increase of 18.56% is expected in the next year compared to the current price of 25.57.

For the next year, analysts expect an EPS growth of 19.98% and a revenue growth 9.96% for ACAD


Analysts
Analysts76.15
Price Target30.32 (18.58%)
EPS Next Y19.98%
Revenue Next Year9.96%

ACAD Ownership

Ownership
Inst Owners103.86%
Ins Owners0.31%
Short Float %6.65%
Short Ratio5.78